NO20054876L - Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser - Google Patents

Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser

Info

Publication number
NO20054876L
NO20054876L NO20054876A NO20054876A NO20054876L NO 20054876 L NO20054876 L NO 20054876L NO 20054876 A NO20054876 A NO 20054876A NO 20054876 A NO20054876 A NO 20054876A NO 20054876 L NO20054876 L NO 20054876L
Authority
NO
Norway
Prior art keywords
drug
compounds
phenyltetrahydroisoquinolines
substituted
preparation
Prior art date
Application number
NO20054876A
Other languages
English (en)
Other versions
NO20054876D0 (no
Inventor
Klaus Wirth
Hans-Jochen Lang
Wendelin Frick
Armin Hofmeister
Markus Bleich
Uwe Heinelt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20054876D0 publication Critical patent/NO20054876D0/no
Publication of NO20054876L publication Critical patent/NO20054876L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med formel I der RI til R9 har de angitte betydninger. Medikamenter inneholdende denne type forbindelse, kan benyttes ved prevensjon eller terapi av forskjellige sykdommer. Forbindelsene kan blant annet benyttes for renale sykdommer som akutt eller kronisk nyresvikt, for forstyrrelser i biliarfunksjonene eller mot respiratoriske forstyrrelser, som snorking eller søvnapne, eller mot apopleksi.
NO20054876A 2003-03-24 2005-10-21 Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser NO20054876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312963A DE10312963A1 (de) 2003-03-24 2003-03-24 Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
PCT/EP2004/002497 WO2004085404A1 (de) 2003-03-24 2004-03-11 Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament

Publications (2)

Publication Number Publication Date
NO20054876D0 NO20054876D0 (no) 2005-10-21
NO20054876L true NO20054876L (no) 2005-12-06

Family

ID=32946086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054876A NO20054876L (no) 2003-03-24 2005-10-21 Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser

Country Status (22)

Country Link
EP (1) EP1613600B1 (no)
JP (1) JP2006521306A (no)
KR (1) KR20050115304A (no)
CN (1) CN100364978C (no)
AR (1) AR043741A1 (no)
AU (1) AU2004224242B2 (no)
BR (1) BRPI0408744A (no)
CA (1) CA2519658A1 (no)
DE (1) DE10312963A1 (no)
HR (1) HRP20050843A2 (no)
MA (1) MA27751A1 (no)
ME (1) MEP42908A (no)
MX (1) MXPA05010003A (no)
MY (1) MY139498A (no)
NO (1) NO20054876L (no)
NZ (1) NZ542608A (no)
PE (1) PE20050311A1 (no)
RS (1) RS20050713A (no)
RU (1) RU2343147C2 (no)
TW (1) TW200510321A (no)
WO (1) WO2004085404A1 (no)
ZA (1) ZA200506422B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012544A1 (de) 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
ES2604542T3 (es) * 2006-06-29 2017-03-07 F. Hoffmann-La Roche Ag Arilamidas con sustitución tetrazol
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
EP2282996A1 (en) * 2008-05-19 2011-02-16 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolines as antimalarial agents
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
DK2748147T3 (da) * 2011-08-25 2017-11-13 St Jude Children's Res Hospital Substitueret 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinolin-4-carboxamider til antimalaria-terapier
SMT201900386T1 (it) * 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
RU2538085C2 (ru) * 2013-05-08 2015-01-10 Любовь Демьяновна Шаманская Препарат для борьбы с экзопаразитами животных
CN106536502B (zh) * 2014-07-25 2019-03-05 大正制药株式会社 被杂芳基取代的苯基四氢异喹啉化合物
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
AU2018205400C1 (en) 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
ES2927100T3 (es) * 2019-05-16 2022-11-02 Lilly Co Eli Compuestos inhibidores del intercambiador de sodio-hidrógeno 3
WO2021021979A2 (en) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Hdac6 inhibitors and uses thereof
EP4504190A4 (en) 2022-04-08 2026-03-25 Eikonizo Therapeutics Inc OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
JPH06256311A (ja) * 1993-02-26 1994-09-13 Nippon Shinyaku Co Ltd イソキノリノール誘導体及び医薬
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
NZ519146A (en) * 1999-11-03 2004-02-27 Albany Molecular Res Inc 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
WO2001032625A1 (en) * 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
DK1453810T3 (da) * 2001-12-05 2009-07-20 Sanofi Aventis Deutschland Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10163992A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline

Also Published As

Publication number Publication date
NO20054876D0 (no) 2005-10-21
HK1090042A1 (en) 2006-12-15
KR20050115304A (ko) 2005-12-07
MY139498A (en) 2009-10-30
ZA200506422B (en) 2007-02-28
WO2004085404A1 (de) 2004-10-07
DE10312963A1 (de) 2004-10-07
NZ542608A (en) 2009-07-31
RS20050713A (sr) 2007-11-15
JP2006521306A (ja) 2006-09-21
RU2006127170A (ru) 2008-02-10
RU2343147C2 (ru) 2009-01-10
BRPI0408744A (pt) 2006-04-18
MEP42908A (en) 2011-02-10
HRP20050843A2 (en) 2006-09-30
CA2519658A1 (en) 2004-10-07
CN100364978C (zh) 2008-01-30
MA27751A1 (fr) 2006-02-01
PE20050311A1 (es) 2005-06-06
AU2004224242A1 (en) 2004-10-07
CN1798737A (zh) 2006-07-05
AR043741A1 (es) 2005-08-10
MXPA05010003A (es) 2005-11-17
EP1613600A1 (de) 2006-01-11
EP1613600B1 (de) 2015-12-23
TW200510321A (en) 2005-03-16
AU2004224242B2 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007007919A3 (en) Heterocyclic janus kinase 3 inhibitors
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006067445A3 (en) Csf-1r kinase inhibitors
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
WO2006064033A3 (en) Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
MX2009004908A (es) Compuestos quimicos.
MY139498A (en) Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
MX2007003157A (es) 4-feniltetrahidroisoquinolinas sustituidas, metodo para su produccion, su uso como medicamento y un medicamento que las contiene.
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
CA2654354C (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
NO20084399L (no) Substituerte 1-amino-4-fenyl-dihydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som et medikament, og medikamenter inneholdende dem
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter